| Literature DB >> 18419829 |
Sven Janno1, Matti M Holi, Katinka Tuisku, Kristian Wahlbeck.
Abstract
BACKGROUND: Neuroleptic-induced movement disorders (NIMDs) have overlapping co-morbidity. Earlier studies have described typical clinical movement patterns for individual NIMDs. This study aimed to identify specific movement patterns for each individual NIMD using actometry.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18419829 PMCID: PMC2374793 DOI: 10.1186/1471-2377-8-10
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Inter-rater reliability coefficients for actometry variables in 99 in-patients with schizophrenia: kappa for categorical and ICC coefficients for continuous measures.
| presence of activity periods | 0.905* |
| presence of rhythmical activity | 0.786* |
| amount of activity periods | 0.967 (0.951–0.978)* |
| dominant frequency | 0.739 (0.624–0.822)* |
| second prevalent frequency | 0.787 (0.672–0.864)* |
| third prevalent frequency | 0.789 (0.672–0.867)* |
| minimal frequency | 0.351 (0.149–0.525)# |
| maximal frequency | 0.831 (0.750–0.887)* |
| highest value of acceleration peaks | 0.841 (0.768–0.893)* |
* p < 0.001
# p = 0.001
Presence of activity periods and rhythmical activity in differentiating neuroleptic-induced movement disorders for 99 in-patients with schizophrenia.
| Presence of activity periods | Presence of rhythmical activity | |
| Pearson chi-square | 5.547 | 2.726 |
| p | 0.035 | 0.099 |
| Pearson chi-square | 5.642 | 5.574 |
| p | 0.016 | 0.019 |
| Pearson chi-square | 0.113 | 4.505 |
| p | 0.714 | 0.034 |
| Pearson chi-square | 1.131 | 1.607 |
| p | 0.495 | 0.254 |
| Pearson chi-square | 0.814 | 2.061 |
| p | 0.685 | 0.151 |
| Pearson chi-square | 8.491 | 11.027 |
| p | 0.004 | 0.001 |
Neuroleptic-induced movement disorders patterns for 99 in-patients with schizophrenia.
| Presence of activity periods n% | Median amount of activity periods IQ* | Presence of rhythmical activity n% | Median of dominant frequency Hz IQ* | Median of second frequency Hz IQ* | Median of third frequency Hz IQ* | Median of minimal frequency Hz IQ* | Median of maximal frequency Hz IQ* | Median highest value of acceleration peaks IQ* | |
| non-movement disorders n = 32 | 25 | 2 | 24 | 0.50 | 0.43 | 0.55 | 0.33 | 0.65 | 106 |
| NIA | 31 | 13 | 30 | 0.58 | 0.60 | 0.70 | 0.38 | 1.15 | 177 |
| NIP | 20 | 8 | 16 | 0.75 | 0.73 | 0.93 | 0.40 | 1.05 | 216 |
| TD | 30 | 9.75 | 29 | 0.55 | 0.55 | 0.65 | 0.40 | 0.95 | 125 |
| PsA | 18 | 16 | 18 | 0.80 | 0.80 | 0.60 | 0.40 | 1.15 | 127 |
| All patients | 88 | 8 | 83 | 0.55 | 0.55 | 0.65 | 0.35 | 0.90 | 129 |
* Interquartile range
The differences in median values of actometric pattern qualities of particular neuroleptic induced movement disorders from non-movement disorder group for 99 in-patients with schizophrenia
| amount of activity periods | dominant frequency | second frequency | maximal frequency | median maximum amplitude | |
| NIA median | 13 | 0.58 | 0.60 | 1.15 | 177 |
| non-NIMD median | 2 | 0.50 | 0.43 | 0.65 | 106 |
| Mann-Whitney U | 207 | 262 | 153 | 177 | 277 |
| p | <0.001 | 0.084 | 0.017 | 0.001 | 0.040 |
| NIP median | 8 | 0.75 | 0.73 | 1.05 | 216 |
| non-NIMD median | 2 | 0.50 | 0.43 | 0.65 | 106 |
| Mann-Whitney U | 282 | 127 | 58 | 143 | 145 |
| p | 0.140 | 0.040 | 0.009 | 0.106 | 0.023 |
| TD median | 9.75 | 0.55 | 0.55 | 0.95 | 127 |
| non-NIMD median | 2 | 0.50 | 0.43 | 0.65 | 106 |
| Mann-Whitney U | 294 | 267 | 163 | 209 | 305 |
| p | 0.003 | 0.145 | 0.030 | 0.013 | 0.110 |
| PsA median | 16 | 0.8 | 0.8 | 1.15 | 144 |
| non-NIMD median | 2 | 0.50 | 0.43 | 0.65 | 106 |
| Mann-Whitney U | 87 | 103 | 82 | 92 | 156 |
| p | < 0.001 | 0.004 | 0.011 | 0.002 | 0.042 |
| NIA and PsA median | 15.75 | 0.68 | 0.60 | 1.15 | 155 |
| non-NIMD median | 2 | 0.50 | 0.43 | 0.65 | 106 |
| Mann-Whitney U | 641 | 364 | 235 | 269 | 433 |
| p | 0.003 | 0.011 | 0.006 | < 0.001 | 0.017 |
Figure 1Receiver Operating Characteristic (ROC) curves for subjective question and lower limb activity count against DSM-IV defined neuroleptic-induced akathisia (NIA).